Two HMRI-affiliated researchers from University of Newcastle have been awarded career fellowships worth more than $1 million for research into innovative cancer treatment.
Funded by the NSW Government and delivered through the Cancer Institute NSW, the fellowships aim to support researchers who are investigating new treatments for people with particularly aggressive forms of cancer.
Career Development Fellowship recipient Dr Kelly Avery-Kiejda was awarded over $550,000 towards the development of a predictive test for p53 and its isoforms to aid the clinical treatment of breast cancer.
Dr Elizabeth Fradgley was recognised with an Early Career Fellowship ($597,000) to continue her work on a multi-component implementation strategy to improve the evidence-based distress management practices of Australian cancer services: the effectiveness and cost of online Training and EducatioNal OutReach visits (The TENOR Trial).
“It is a fantastic reflection on HMRI and also the Hunter Cancer Research Alliance since Kelly and I were both supported by a philanthropic donation via HCRA last year. Just another example of how the generosity of the Hunter community powers young researchers.”
Professor David Currow, Chief Cancer Officer and CEO of the Cancer Institute NSW, said the fellowships were about supporting the very best researchers to pursue promising treatments for people living with cancer.
“Their research will have an enormous, tangible impact on the community. Our goal is that it will help stop the spread of cancer and lessen its impact across the state,” Professor Currow said.